-transparent.png){kind=logo}
Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2). 2005
David R Anderson, and
Shridhar Hegde, and
Emily Reinhard, and
Leslie Gomez, and
William F Vernier, and
Len Lee, and
Shuang Liu, and
Aruna Sambandam, and
Patricia A Snider, and
Liaqat Masih
Pfizer Global Research and Development, 700 Chesterfield Parkway W, Chesterfield, MO 63017, USA. david.r.anderson@pfizer.com
A class of inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2) was discovered. These compounds have demonstrated activity against the enzyme with IC50 values as low as 130 nM and suppress the expression of TNFalpha in U937 cells. These represent the first small molecule inhibitors of MK-2 to be reported.
Related Publications
David R Anderson, and
Shridhar Hegde, and
Emily Reinhard, and
Leslie Gomez, and
William F Vernier, and
Len Lee, and
Shuang Liu, and
Aruna Sambandam, and
Patricia A Snider, and
Liaqat Masih
May 2007,
Journal of medicinal chemistry,
David R Anderson, and
Shridhar Hegde, and
Emily Reinhard, and
Leslie Gomez, and
William F Vernier, and
Len Lee, and
Shuang Liu, and
Aruna Sambandam, and
Patricia A Snider, and
Liaqat Masih
May 2009,
Bioorganic & medicinal chemistry,
David R Anderson, and
Shridhar Hegde, and
Emily Reinhard, and
Leslie Gomez, and
William F Vernier, and
Len Lee, and
Shuang Liu, and
Aruna Sambandam, and
Patricia A Snider, and
Liaqat Masih
November 2015,
Bioorganic & medicinal chemistry letters,
David R Anderson, and
Shridhar Hegde, and
Emily Reinhard, and
Leslie Gomez, and
William F Vernier, and
Len Lee, and
Shuang Liu, and
Aruna Sambandam, and
Patricia A Snider, and
Liaqat Masih
June 2009,
Bioorganic & medicinal chemistry letters,
David R Anderson, and
Shridhar Hegde, and
Emily Reinhard, and
Leslie Gomez, and
William F Vernier, and
Len Lee, and
Shuang Liu, and
Aruna Sambandam, and
Patricia A Snider, and
Liaqat Masih
February 2011,
Expert opinion on investigational drugs,
David R Anderson, and
Shridhar Hegde, and
Emily Reinhard, and
Leslie Gomez, and
William F Vernier, and
Len Lee, and
Shuang Liu, and
Aruna Sambandam, and
Patricia A Snider, and
Liaqat Masih
August 2010,
Bioorganic & medicinal chemistry letters,
David R Anderson, and
Shridhar Hegde, and
Emily Reinhard, and
Leslie Gomez, and
William F Vernier, and
Len Lee, and
Shuang Liu, and
Aruna Sambandam, and
Patricia A Snider, and
Liaqat Masih
June 2007,
Current opinion in pharmacology,
David R Anderson, and
Shridhar Hegde, and
Emily Reinhard, and
Leslie Gomez, and
William F Vernier, and
Len Lee, and
Shuang Liu, and
Aruna Sambandam, and
Patricia A Snider, and
Liaqat Masih
February 2017,
JAMA oncology,
David R Anderson, and
Shridhar Hegde, and
Emily Reinhard, and
Leslie Gomez, and
William F Vernier, and
Len Lee, and
Shuang Liu, and
Aruna Sambandam, and
Patricia A Snider, and
Liaqat Masih
July 2008,
Expert opinion on drug discovery,
David R Anderson, and
Shridhar Hegde, and
Emily Reinhard, and
Leslie Gomez, and
William F Vernier, and
Len Lee, and
Shuang Liu, and
Aruna Sambandam, and
Patricia A Snider, and
Liaqat Masih
November 1992,
The EMBO journal,
